bluuebunny/crossref_metadata_2025_split huggingface dataset:
Central nervous system stem cell transplantation for children with neuronal ceroid lipofuscinosis
Authors: Selden Nathan R. , Al-Uzri Amira , Huhn Stephen L. , Koch Thomas K. , Sikora Darryn M. , Nguyen-Driver Mina D. , Guillaume Daniel J. , Koh Jeffrey L. , Gultekin Sakir H. , Anderson James C. , Vogel Hannes , Sutcliffe Trenna L. , Jacobs Yakop , Steiner Robert D. 
Published: April 2013

Object
Infantile and late-infantile neuronal ceroid lipofuscinoses (NCLs) are invariably fatal lysosomal storage diseases associated with defects in lysosomal enzyme palmitoyl-protein thioesterase 1 (PPT-1) or tripeptidyl peptidase 1 (TPP1) activity. Previous preclinical studies have demonstrated that human CNS stem cells (HuCNS-SCs) produce both PPT-1 and TPP1 and result in donor cell engraftment and reduced accumulation of storage material in the brain when tested in an NCL mouse model.

Methods
HuCNS-SC transplantation was tested in an open-label dose-escalation Phase I clinical trial as a potential treatment for infantile and late-infantile NCL. Study design included direct neurosurgical transplantation of allogeneic HuCNS-SCs into the cerebral hemispheres and lateral ventricles accompanied by 12 months of immunosuppression.

Results
Six children with either the infantile or late-infantile forms of NCL underwent low- (3 patients) and high- (3 patients) dose transplantation of HuCNS-SCs followed by immunosuppression. The surgery, immunosuppression, and cell transplantation were well tolerated. Adverse events following transplantation were consistent with the underlying disease, and none were directly attributed to the donor cells. Observations regarding efficacy of the intervention were limited by the enrollment criteria requiring that patients be in advanced stages of disease.

Conclusions
This study represents the first-in-human clinical trial involving transplantation of a purified population of human neural stem cells for a neurodegenerative disorder. The feasibility of this approach and absence of transplantation-related serious adverse events support further exploration of HuCNS-SC transplantation as a potential treatment for select subtypes of NCL, and possibly for other neurodegenerative disorders. Clinical trial registration no.: NCT00337636 (ClinicalTrials.gov).
Ornament, Representation, and Imaginary Animals in Bronze Age China
Authors: Bagley Robert W. 
Published: April 2013

Décor, représentation et animaux imaginaires dans la Chine à l'âge du Bronze
Dans l'art de la Chine à l'âge du Bronze - entre environ 1500 et 200 avant notre ère -, les animaux imaginaires prédominent. À la fin de la période, le plus important de ces animaux était le dragon, qui était parvenu alors à une forme comparable à celle du lézard, forme qui nous est aujourd'hui familière, puisque c'est le «dragon chinois» des Han et des époques postérieures. Cependant, ce dragon était inconnu au début de la période. Les animaux imaginaires inventés par les artisans du bronze de la phase Erligang (env. 1500-1300 av. J.-C.) sont radicalement différents des dragons Han, et ce sont les motifs de Erligang qui façonnent le développement de l'art durant le premier millénaire de l'âge du Bronze. Pourtant, la rupture entre la tradition artistique qui apparaît durant la phase Erligang et la tradition plus familière qui la suit n'a pas été bien perçue. Une partie du problème vient de notre habitude d'appliquer le mot «dragon» indistinctement aux motifs de Erligang et à ceux des Han (206 av.-220 apr. J.-C), habitude qui nous pousse insensiblement à admettre que ces motifs sont pour l'essentiel une seule et même chose. De fait, certains chercheurs les pensent, sans y prêter attention, comme des représentations différentes d'un même animal, en oubliant que les dragons ne sauraient être représentés puisqu'ils n'existent pas dans la nature. Les chercheurs qui pensent de cette manière expliquent ces motifs zoomorphes curieusement vagues comme des représentations «stylisées» d'animaux que les périodes postérieures ont figurés avec plus de fidélité. En d'autres termes, ils s'imaginent que l'artiste de Erligang visualisait le lézard recouvert d'écaillés tel qu'il est connu aux époques postérieures, mais que pour une raison quelconque il a choisi de le représenter seulement d'une façon abstraite et schématique. Cette façon de penser refuse de prendre les témoins visuels de Erligang comme ils sont. Ce faisant, elle passe à côté de la nouveauté représentée par les animaux crédibles et prosaïques qui commencent d'apparaître à l'époque des Royaumes combattants. Cet article a pour thèse que les animaux imaginaires du ve siècle avant notre ère et après se distinguent de leurs prédécesseurs par un changement fondamental de caractère, et que la raison principale de ce changement tient à l'influence des steppes et du Proche-Orient, influence qui a transformé quelque chose d'étrange en quelque chose de familier. Cette transformation apportée par ce stimulant étranger nous échappe tant qu'on n'examine pas l'art de la phase Erligang soigneusement et selon ses propres termes, sans se laisser influencer par notre connaissance de ce qui a suivi. Aussi bien pour elle-même que pour comprendre ce qui s'est passé ensuite, l'étrangeté de la tradition artistique de Erligang doit être abordée de façon directe.
Vaginal Progesterone for Pregnancy Prolongation After Arrested Preterm Labor
Authors: Nachum Zohar , Ganor Paz Yael , Massalha Manal , Wated Malak , Harel Noa , Yefet Enav 
Published: July 2024

ImportanceWomen with arrested preterm labor (APTL) are at very high risk for spontaneous preterm delivery (SPTD), the leading cause of neonatal mortality and morbidity. To date, no maintenance therapy has been found to be effective for pregnancy prolongation. A few clinical trials with considerable methodological limitations have demonstrated some efficacy for 400 mg vaginal micronized progesterone (VMP) in women with APTL.ObjectiveTo investigate the effectiveness of daily 400 mg VMP for the prolongation of pregnancy after APTL.Design, Setting, and ParticipantsThis randomized clinical trial was conducted between December 19, 2018, and February 27, 2023, in 3 university-affiliated medical centers in Israel. Participants included women with singleton and twin pregnancies after APTL following tocolysis at 24 weeks 0 days to 34 weeks 0 days’ gestation. Women with a history of preterm delivery or asymptomatic cervical shortening in the current pregnancy were excluded.InterventionsParticipants were randomly allocated to receive VMP 200 mg twice a day or no treatment until 36 weeks 6 days’ gestation.Main Outcomes and MeasuresThe primary end points were mean number of days from study enrollment to delivery and the rate of SPTD prior to 37 weeks’ gestation.ResultsA total of 129 participants were enrolled (65 in the VMP group and 64 in the no-treatment group). Mean (SD) age was 27.6 (5.1) years. Between the VMP and no-treatment groups, there was no difference in pregnancy prolongation (mean [SD], 40.0 [17.8] vs 37.4 [20.3] days; P = .44) and the rate of SPTD (16 [25%] vs 19 [30%]; relative risk, 0.8; 95% CI, 0.5-1.5; P = .52). In twin pregnancies, including 12 and 15 pairs in the VMP and no-treatment groups, respectively, VMP prolonged pregnancy (mean [SD], 43.7 [18.1] vs 26.1 [15.2] days; P = .02), postponed the delivery week (36.5 [1.4] vs 34.7 [2.2] weeks; P = .01), shortened the length of stay in the neonatal intensive care unit (4.9 [10.6] vs 13.2 [18.5] days; P = .03) and overall hospital stay (8.3 [9.6] vs 15.1 [17.2] days; P = .03), and was associated with a higher birth weight (2444 [528] vs 2018 [430] g; P = .01).Conclusions and RelevanceThese findings show that VMP given in a dosage of 200 mg twice a day following APTL is not an effective treatment to prolong pregnancy or prevent SPTD. However, VMP demonstrated beneficial effects in twin pregnancies, warranting further investigation.Trial RegistrationClinicalTrials.gov Identifier: NCT02430233
Direct-Acting Oral Anticoagulants and Antiseizure Medications for Atrial Fibrillation and Epilepsy and Risk of Thromboembolic Events
Authors: Acton Emily K. , Hennessy Sean , Gelfand Michael A. , Leonard Charles E. , Bilker Warren B. , Shu Di , Willis Allison W. , Kasner Scott E. 
Published: July 2024

ImportanceDirect-acting oral anticoagulants (DOACs) are commonly prescribed with antiseizure medications (ASMs) due to concurrency of and the association between atrial fibrillation (AF) and epilepsy. However, enzyme-inducing (EI) ASMs may reduce absorption and accelerate metabolism of DOACs, potentially lowering DOAC levels and elevating thromboembolism risk.ObjectiveTo assess the rates of thromboembolic and major bleeding events in adults with AF and epilepsy dispensed DOACs and EI ASMs vs DOACs with non-EI ASMs.Design, Setting, and ParticipantsThis active-comparator, new-user cohort study included US health care data from the Clinformatics Data Mart database from October 2010 to September 2021 for a nationally representative population of adults with AF and epilepsy.ExposureEvaluations included episodes of contiguous coadministration of DOACs for AF with EI ASMs (exposed) or non-EI ASMs (referent) for epilepsy.Main Outcomes and MeasuresThromboembolic events (primary outcome) and major bleeding events (secondary outcome) were identified based on a series of validated, diagnosis-based coding algorithms. Data-adaptive, high-dimensional propensity score matching was used to control for observed confounders and proxies for unobserved confounders. Adjusted hazard ratios (AHRs) were estimated using Cox proportional hazards regression models with robust variance estimators to account for clustering within matched pairs.ResultsThis study included 14 078 episodes (median age, 74 [IQR, 67-81]; 52.4% female) and 14 158 episodes (median age, 74 [IQR, 67-81]; 52.4% female) of incident DOAC and ASM use that met eligibility criteria for assessment of thromboembolic and major bleeding outcomes, respectively. Incidence was 88.5 per 1000 person-years for thromboembolic events and 68.3 per 1000 person-years for bleeding events. Compared with use of non-EI ASMs, use of EI ASMs with DOACs was not associated with a difference in risk of thromboembolic events (AHR, 1.10; 95% CI, 0.82-1.46) but was associated with a reduction in risk of major bleeding events (AHR, 0.63; 95% CI, 0.44-0.89).Conclusions and RelevanceIn this cohort study, EI ASMs were not associated with alteration in DOAC efficacy. Further research is needed on the reduction in bleeding risk associated with EI ASMs, as this may suggest that pharmacokinetic interactions are associated with lowering DOAC levels without negating therapeutic effects.
Relationship between Jo‐1 B Cell Epitope Profile and Clinical Features of Anti‐Synthetase Syndrome
Authors: Yamaguchi Koichi , Tang Qi , LaConti Joseph J. , Kippelen Fanny , Zhu Lei , Poland Paul , Hartoyo Mara , Aggarwal Rohit , Oddis Chester V. , Ascherman Dana P. 
Published: July 2024

ObjectiveAnti–histidyl‐transfer RNA synthetase (Jo‐1) antibodies are associated with myositis as well as different extramuscular organ complications comprising the anti‐synthetase syndrome. This study aimed to clarify the relationship between anti–Jo‐1 epitope recognition patterns and specific clinical features of this syndrome.MethodsB cell epitope mapping was performed via enzyme‐linked immunosorbent assay in 180 patients who were anti–Jo‐1 antibody‐positive using overlapping peptides/protein fragments spanning the amino‐terminal 151 amino acids of Jo‐1 as substrate antigens. Statistical associations with clinical features were assessed through rank‐sum, correlation, and cluster analyses.ResultsThe level of reactivity against subfragments spanning amino acids 1–151 of Jo‐1 paralleled that of full‐length Jo‐1, confirming the immunodominance of this amino‐terminal region. The corresponding frequencies of reactivity to peptides 1 (amino acids [aa] 1–21), 3 (aa 27–47), 4 (aa 40–60), 10 (aa 118–138), and 11 (aa 131–151) were 6.1%, 42.5%, 6.8%, 6.7%, and 20.3%. While anti–full‐length Jo‐1 antibodies were significantly associated with Raynaud phenomenon, anti‐fragment A2 (aa 1–60) and A3 (aa 1–90) antibodies were associated with proximal muscle weakness, Raynaud phenomenon, arthritis, and sicca syndrome. Anti‐fragment A4 (aa 1–120) and A5 (aa 1–151) antibodies were also associated with sicca syndrome. Peptide 1 (aa 1–21) antibodies were associated with Raynaud phenomenon and dysphagia. Whereas anti‐peptide 3 (aa 27–47) antibodies were also linked to Raynaud phenomenon, anti‐peptide 9 (aa 105–125) antibodies were associated with mechanic's hands.ConclusionAutoantibodies targeting different amino‐terminal subfragments and/or peptides of Jo‐1 were associated with specific clinical features of the anti‐synthetase syndrome, demonstrating the biomarker potential of B cell epitope profiling in this disorder.
Near‐Infrared Afterglow Luminescence Amplification via Albumin Complexation of Semiconducting Polymer Nanoparticles for Surgical Navigation in Ex Vivo Porcine Models
Authors: Bendele Nathaniel , Kitamura Ken , Vasquez Isabella , Harun Asma , Carroll McKenzie , Srivastava Indrajit 
Published: July 2024

AbstractAfterglow imaging, leveraging persistent luminescence following light cessation, has emerged as a promising modality for surgical interventions. However, the scarcity of efficient near‐infrared (NIR) responsive afterglow materials, along with their inherently low brightness and lack of cyclic modulation in afterglow emission, has impeded their widespread adoption. Addressing these challenges requires a strategic repurposing of afterglow materials that improve on such limitations. Here, an afterglow probe, composed of bovine serum albumin (BSA) coated with an afterglow material, a semiconducting polymer dye (SP1), called BSA@SP1 demonstrating a substantial amplification of the afterglow luminescence (≈3‐fold) compared to polymer‐lipid coated PFODBT (DSPE‐PEG@SP1) under same experimental conditions is developed. This enhancement is believed to be attributed to the electron‐rich matrix provided by BSA that immobilizes SP1 and enhances the generation of 1O2 radicals, which improves the afterglow luminescence brightness. Through molecular docking, physicochemical characterization, and optical assessments, BSA@SP1's superior afterglow properties, cyclic afterglow behavior, long‐term colloidal stability, and biocompatibility are highlighted. Furthermore, superior tissue permeation profiling of afterglow signals of BSA@SP1's compared to fluorescence signals using ex vivo tumor‐mimicking phantoms and various porcine tissue types (skin, muscle, and fat) is demonstrated. Expanding on this, to showcase BSA@SP1's potential in image‐guided surgeries, tumor‐mimicking phantoms within porcine lungs and conducted direct comparisons between fluorescence and afterglow‐guided interventions to illustrate the latter's superiority is implanted. Overall, the study introduces a promising strategy for enhancing current afterglow materials through protein complexation, resulting in both ultrahigh signal‐to‐background ratios and cyclic afterglow signals.
CO2‐Mediated Hydrogen Energy Release‐Storage Enabled by Arc‐Discharge‐Synthesized High‐Dispersion Platinum Catalysts
Authors: Xia Yucheng , Luo Rui , Fu Yang , Pan Yidong , Hao Weiju , Fan Jinchen , Bi Qingyuan , Li Guisheng 
Published: July 2024

AbstractDeveloping and fabricating a heterogeneous material for efficient dehydrogenation of formic acid (FA) to H2 coupled with hydrogenation of CO2 back to FA is a promising strategy to forming a carbon‐neutral CO2‐mediated hydrogen energy release‐storage system, which remains challenging. Herein, a facile one‐step ultrahigh‐temperature method of arc‐discharge route for synthesizing efficient single‐crystal α‐MoC supported platinum catalysts with high dispersion of Pt single atoms (SAs), nanoclusters (NCs), and nanoparticles (NPs) is reported. These catalysts exhibit remarkable performance for the adsorption properties and chemical conversion of small molecules including room‐temperature FA dehydrogenation, CO2 hydrogenation to FA (formate), and low‐temperature CO oxidation reactions. The enhanced electron transfer from MoC to active Pt species improves catalyst's surface electron density, thus modulating the chemical adsorption of these small molecules. The engineered 0.1Pt/MoC with Pt SAs shows an outstanding FA dehydrogenation efficiency, with ca. 100% FA conversion and an initial TOF of up to 7739 h−1 at 25 °C. The versatile 0.1Pt/MoC also displays the ability for converting CO2 hydrogenation back to the hydrogen storage carrier FA (formate) with 88.3% yield under mild conditions. Moreover, in‐depth insights into the material microstructure, Pt−MoC electronic interactions, reaction‐dependent particle size effect, and adsorption energy are comprehensively investigated.
Programmable Plasmonic Hydrogel Thermometers Actuated by DNA Breathing
Authors: Wang Luyang , Wang Zhen , Liu Feng , Zhang Xinrui , Huang Jihong , Wang Guoqing 
Published: July 2024

AbstractNanothermometry explores the use of temperature‐dependent properties of materials for remote and sensitive thermal readout at the nanoscale. The currently established nanothermometers are largely limited by uncontrollable nanoparticle flocculation, complex experimental setup, and narrow working temperature range. Here it is shown that gold nanoparticles (e.g., spheres, rods) embedded in a hydrogel can afford sensitive, durable, and range‐tunable temperature sensing via the terminal breathing of the nanoparticle surface‐grafted DNA. The realization of the plasmonic hydrogel thermometer with a thermal sensitivity of ≤2 °C relies on the dynamically modulable interparticle spacing by thermo‐responsive terminal base pairing/unpairing of the surface DNA. By altering the alcoholic ratio of the hydrogel, the temperature‐response range can be continuously regulated based on solvent‐mediated DNA base pairing. Compared with the colloidal counterpart, importantly, the hydrogel thermometer exhibits greatly improved thermal sensing capability (e.g., repeatability ≥50 times) while possessing excellent durability. Given the excellent durability, high sensitivity, and programmable temperature response range, the thermometers actuated by DNA breathing for advanced uses in human sensing and optoelectronics are within reach.
PA2PbBr4/MAPbBr3 Heterojunction X‐Ray Detector with Enhanced Sensitivity and Excellent Self‐Powered Functionality
Authors: He Ningfang , Zhang Longzhen , He Xin , Guo Jiahao , Wu Xiaochao , Li Qingkui , He Jilin 
Published: July 2024

AbstractHeterojunctions combining 2D and 3D perovskites have caused a surge in the research on X‐ray detectors. The enhanced charge transport facilitated by the built‐in electric field further amplifies the potential of this material system, paving the way for highly sensitive and efficient X‐ray detectors. In this study, PA2PbBr4 single‐crystal film with a thickness of 10 µm is successfully grown on the surface of MAPbBr3 substrate via liquid phase epitaxial method, forming a 2D/3D heterojunction. This innovative detector exhibits a dramatically enhanced sensitivity of 3.81 × 104 µC Gy−1 cm−2 at an X‐ray tube voltage of 70 keV and a bias of 50 V mm−1, along with an ultra‐low detection limit of 11.84 nGy s−1, surpassing the performance of the conventional MAPbBr3 X‐ray detectors by a factor of four and 2 × 103 times higher than that of commercialized α‐Se detectors. Furthermore, the 2D/3D heterojunction exhibits exceptional self‐powered X‐ray detection capabilities, achieving a remarkable sensitivity of 3562.26 µC Gy−1 cm−2 at 70 keV X‐ray tube voltage. This superior performance implies reduced energy consumption, high portability, decreased ion migration, and provides inspiration for the next generation of high‐performance X‐ray detectors.
Multicolor Polymer Mechanochromism from an Ultrasensitive Concentration‐Dependent Excited State Intramolecular Proton Transfer Mechanophore
Authors: Chen Mingzhi , Hu Huan , Cheng Xin , Wu Yu , Ma Zhimin , Sijbesma Rint P. , Ma Zhiyong 
Published: July 2024

AbstractAn ultrasensitive concentration‐dependent ESIPT mechanochromic mechanophore (MM) NaMz (4‐amino‐2‐(1H‐naphtho[2,3‐d]imidazol‐2‐yl)phenol), which exhibits real‐time and reversible multicolor mechanochromism in polyurethane is reported. NaMz has one single link point and can be obtained facilely by one‐step reaction. As the concentration of NaMz increased from 0.01 to 0.05 mol%, the intensity ratio IE/IK of enol emission to keto emission changed significantly and concentration‐dependent multicolor fluorescence (yellow, white, blue) can be realized. Then, a simple strategy, force‐tuning the aggregation state of NaMz molecules, to adjust the ESIPT process to achieve ultrasensitive colorful mechanochromism is proposed. Intriguingly, force‐tuned white light emitting can be realized for 0.035 mol%NaMz@PU. Because the extended conjugation structure, NaMz@PU shows a red‐shifted keto emission at 541 nm with a larger Stoke shift compared with PhMz‐NH2@PU, which is also the key to multicolor concentration‐dependent polymer mechanochromism of NaMz@PU. Control experiments of NaMz‐OH@PU and NaMz‐3OH@PU show that the aliphatic hydroxyl group on the naphthimidazole moiety impedes the planarization of molecular structure and thus hinders aggregation, further verifying that the multicolor concentration‐dependent mechanochromism of NaMz@PU is indeed caused by force induced disaggregation. The excellent color‐changing effect, real‐time reversible force‐optical coupling and precise regulation of this study will make a new contribution to polymer mechanochemistry.
Tackling SARS‐CoV‐2: Deep Purpose Virtual Screening Identified Compounds to Target the Glycosylated Full‐Length GRP78
Authors: Elshemey Wael M. , Ibrahim Ibrahim M. , Ezat Ahmed A. , Elgohary Alaa M. , Elfiky Abdo A. , Nassar Aaya M. 
Published: July 2024

AbstractThe glucose‐regulated protein 78 (GRP78) is pivotal in endoplasmic reticulum protein homeostasis and the unfolded protein response during cellular stress. Experimental validation has shown its role in SARS‐CoV‐2 attachment and entry. Here, the full GRP78 sequence, adding carbohydrate sugars to nucleotide‐binding domain sites, and conduct molecular dynamics simulations is modeled. Utilizing DeepPurpose virtual screening on the COCONUT database, followed by blind structure‐based screening with AutoDock Vina, top interacting binders is identified. Molecular dynamic simulations with MM/GBSA reveal stable binding of CNP0339053 and CNP0400762 to GRP78 (free energies of −43.5 ±6.7 and −34.8 ±3.9 kcal mol−1, respectively). These compounds hold promise as safe antiviral treatments for COVID‐19.